Journal of International Psychiatry

[Abstract]Objective:To discuss the impact of non-motor symptoms in old patients with parkin son s disease treated with madopar combined pramipexole.Methods:72 old patients with parkin son s disease from June 2014 to January 2016 were randomly selected and divided into 36 patients of them treated wih madopar only were taken as control group,while the other 36 patients of them treated with madopar combined pramipexole were taken as research group.Compared the scores of NMSQuest, HAMD, MMSE, PQSI and SCOPA-AUT with two groups before and after treatments,detected the levels of IL-1βand IL-6 before and after treatments in two groups.Observed the adverse reactions in two groups during the treatments.Results:The scores of NMSQuest、HAMD and PQSI were (14.28±1.96),(9.23±2.58) and (4.46±1.24) in research group after treatments,which were lower than that in control group(P＜0.05).The scores of MMSE and SCOPA-AUT in two groups after treatments were without statistical significance.(P＞0.05).The levels of IL-1βand IL-6 were (10.54±1.43)pg/mL and (4.96±0.64)pg/L in research gorup after treatments ,which were lower than that in control group(P＜0.05).The occurrence rate of adverse reactions was 5.56% in research group ,which is lower that in control group,but differences were without statistical significance(P＞0.05).Conclusions:Old patients with parkin son s disease in treatments of madopar combined pramipexole can improve non-motor symptoms and reduce the levels of IL-1βand IL-6 with effective and safety,which is worthy of clinical use.

[Keywords] Madopar;Pramipexole;Parkinson s disease;Non-motor symptoms